Literature DB >> 22294856

Synthesis, Crystal Structure, and Rotational Energy Profile of 3-Cyclopropyl-1,2,4-benzotriazine 1,4-Di-N-oxide.

Ujjal Sarkar1, Rainer Glaser, Zack D Parsons, Charles L Barnes, Kent S Gates.   

Abstract

1,2,4-Benzotriazine 1,4-di-N-oxides are potent antitumor drug candidates that undergo in vivo bioreduction leading to selective DNA damage in the low oxygen (hypoxic) cells found in tumors. Tirapazamine (TPZ) is the lead compound in this family. Here we report on the synthesis, crystal structure, and conformational analysis of a new analog, 3-cyclopropyl-1,2,4-benzotriazine 1,4-di-N-oxide (3). Compound 3 (C(10)H(10)N(3)O(2)) crystallized in the monoclinic space group C2/c. Unit cell parameters for 3: a = 16.6306 (12), b = 7.799 (5), c = 16.0113 (11) Å, α = 90, β = 119.0440 (10), γ = 90, and z = 8.

Entities:  

Year:  2010        PMID: 22294856      PMCID: PMC3268128          DOI: 10.1007/s10870-010-9707-9

Source DB:  PubMed          Journal:  J Chem Crystallogr        ISSN: 1074-1542            Impact factor:   0.603


  20 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Molecular structure and conformation of cyclopropylbenzene as determined by ab initio molecular orbital calculations, pulsed-jet fourier transform microwave spectroscopic, and gas-phase electron diffraction investigations.

Authors:  Q Shen; C Wells; M Traetteberg; R K Bohn; A Willis; J Knee
Journal:  J Org Chem       Date:  2001-08-24       Impact factor: 4.354

3.  Photosensitization of guanine-specific DNA damage by a cyano-substituted quinoxaline di-N-oxide.

Authors:  T Fuchs; K S Gates; J T Hwang; M M Greenberg
Journal:  Chem Res Toxicol       Date:  1999-12       Impact factor: 3.739

Review 4.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.

Authors:  J M Brown
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

Review 5.  Tirapazamine: from bench to clinical trials.

Authors:  Loredana Marcu; Ian Olver
Journal:  Curr Clin Pharmacol       Date:  2006-01

6.  DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Authors:  Mustafa Birincioglu; Pawel Jaruga; Goutam Chowdhury; Henry Rodriguez; Miral Dizdaroglu; Kent S Gates
Journal:  J Am Chem Soc       Date:  2003-09-24       Impact factor: 15.419

7.  Direct evidence for bimodal DNA damage induced by tirapazamine.

Authors:  J S Daniels; K S Gates; C Tronche; M M Greenberg
Journal:  Chem Res Toxicol       Date:  1998-11       Impact factor: 3.739

Review 8.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

9.  Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction.

Authors:  Robert F Anderson; Sujata S Shinde; Michael P Hay; Swarna A Gamage; William A Denny
Journal:  J Am Chem Soc       Date:  2003-01-22       Impact factor: 15.419

10.  Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.

Authors:  Michael P Hay; Karin Pchalek; Frederik B Pruijn; Kevin O Hicks; Bronwyn G Siim; Robert F Anderson; Sujata S Shinde; Victoria Phillips; William A Denny; William R Wilson
Journal:  J Med Chem       Date:  2007-12-06       Impact factor: 7.446

View more
  1 in total

1.  Synthesis and anticancer evaluation of some novel pyrimido[5,4-e][1,2,4]triazines and pyrazolo[3,4-d]pyrimidine using DMF-DMA as methylating and cyclizing agent.

Authors:  Samar A El-Kalyoubi
Journal:  Chem Cent J       Date:  2018-05-23       Impact factor: 4.215

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.